Activity Overview
The Interstitial Lung Disease Insights: Meet the Professor Virtual Series I, is a live, case-based program designed to enhance clinicians’ ability to recognize and manage interstitial lung disease associated with systemic autoimmune rheumatic diseases. Through expert-led presentations, the series highlights evidence-based approaches to early detection, risk-based screening, diagnostic evaluation, and longitudinal care, while promoting interdisciplinary collaboration and informed clinical decision-making to improve patient outcomes.
This session builds on these foundations by focusing on the early detection, diagnosis, and management of interstitial lung disease using a case-based approach. Faculty will demonstrate how to integrate clinical presentation, laboratory and autoantibody testing, imaging, and pulmonary function data to improve diagnostic accuracy, guide risk-based screening, and apply practical strategies for monitoring, prognosis, and multidisciplinary care.
Learning Objectives
Upon completion of this activity, participants should be able to:
Recognize the burden of SARD ILD in autoimmune diseases
Implement current guidelines to optimize early detection and establish best practices
Apply risk based screening approaches
Implement practical monitoring protocols, including those for interprofessional teams
Promote interdisciplinary collaboration, pathways for access to care, and patient education around early detection of SARD ILD
Establish effective workflows to reduce barriers for early detection and treatment of SARD ILD
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by September 21, 2029, at 11:59 PM ET.
All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity.
Available Credit
CME: 1.50 AMA PRA Category 1 Credit(s)™
ABIM MOC: 1.50 Medical Knowledge Points
ANCC: 1.50 Contact Hours
AAPA: 1.50 AAPA Category 1 CME ™ Credits
AMA Designation Statement
The American College of Rheumatology designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
ANCC Designation Statement
The American College of Rheumatology designates this enduring material for a maximum of 1.50 ANCC contact hours.
AAPA Designation Statement
Through joint accreditation, the American College of Rheumatology has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME ™ credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME™ credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Interstitial Lung Disease Insights: Meet the Professor Virtual Series I On Demand Faculty Disclosure Mitigation
Acknowledgement of Commercial Support
TBD
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
The Interstitial Lung Disease Insights: Meet the Professor Virtual Series I, is a live, case-based program designed to enhance clinicians’ ability to recognize and manage interstitial lung disease associated with systemic autoimmune rheumatic diseases. Through expert-led presentations, the series highlights evidence-based approaches to early detection, risk-based screening, diagnostic evaluation, and longitudinal care, while promoting interdisciplinary collaboration and informed clinical decision-making to improve patient outcomes.
This session builds on these foundations by focusing on the early detection, diagnosis, and management of interstitial lung disease using a case-based approach. Faculty will demonstrate how to integrate clinical presentation, laboratory and autoantibody testing, imaging, and pulmonary function data to improve diagnostic accuracy, guide risk-based screening, and apply practical strategies for monitoring, prognosis, and multidisciplinary care.
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe risk based screening and monitoring strategies
Apply stepwise treatment algorithms for SARD ILD
Recognize contraindicated therapies and avoid harm
Integrate antifibrotics and immunosuppressants with an evidence based approach
Enhance interprofessional and interdisciplinary care and patient centered decision making
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by September 21, 2029, at 11:59 PM ET.
All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity.
Available Credit
CME: 1.50 AMA PRA Category 1 Credit(s)™
ABIM MOC: 1.50 Medical Knowledge Points
ANCC: 1.50 Contact Hours
AAPA: 1.50 AAPA Category 1 CME ™ Credits
AMA Designation Statement
The American College of Rheumatology designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
ANCC Designation Statement
The American College of Rheumatology designates this enduring material for a maximum of 1.50 ANCC contact hours.
AAPA Designation Statement
Through joint accreditation, the American College of Rheumatology has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME ™ credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME™ credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Interstitial Lung Disease Insights: Meet the Professor Virtual Series II On Demand Faculty Disclosure Mitigation
Acknowledgement of Commercial Support
TBD
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
This recording of a one-hour webinar features panelists discussing interstitial lung disease (ILD) fundamentals, including disparities, symptom recognition and differential diagnosis, as well as the ACR ILD guidelines. Additionally, the webinar emphasizes strategies to enhance care coordination across multidisciplinary teams to enhance collaboration between primary care, rheumatology and pulmonology.
Learning Objectives
Upon completion of this activity, participants should be able to:
Identify health disparities in ILD
Summarize treatment recommendations from the ACR ILD guidelines
Discuss how multidisciplinary care teams, including rheumatology and pulmonology, can improve patient care
Target Audience
Advanced practice nurses, fellows in training, physician assistants, primary care providers, resident, rheumatologists, and rheumatology interprofessionals
CE & MOC Information
This activity is not eligible for credit.
Acknowledgement of Commercial Support
This event was made possible by financial support from Boehringer Ingelheim.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
This recorded webinar explores the expanding role of glucagon-like peptide-1 receptor agonists beyond diabetes and obesity, with a focus on their relevance in rheumatology care. Designed for rheumatologists, endocrinologists, pharmacists, advanced practice providers, and primary care clinicians, the session examines the intersection of metabolic disease and inflammatory conditions through a case-based, clinically practical lens. Key themes include glucagon-like peptide-1 receptor agonists, rheumatology, obesity, inflammatory arthritis, osteoarthritis, metabolic disease, interdisciplinary care, pharmacotherapy, access, safety, ethics, and clinical decision-making.
Through expert-led presentations, this activity highlights emerging evidence and practical applications in rheumatic disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
Explain the metabolic and systemic mechanisms of GLP 1 receptor agonists relevant to rheumatology patients
Evaluate emerging evidence in osteoarthritis, inflammatory arthritis, and comorbid conditions
Identify appropriate patient candidates and interdisciplinary care considerations
Assess access barriers, safety issues, and ethical implications
Apply case-based frameworks for real-world clinical decision-making
CE & MOC Information
This activity is not eligible for credit.
Acknowledgement of Commercial Support
TBD
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
The Pediatric Rheumatology Symposium (PRSYM) Highlights will provide up-to-date, practical clinical information and basic science knowledge on the diagnosis and management of pediatric patients with rheumatic diseases and immune disorders.
Topics
Addressing Key Issues in Pediatric Rheumatology
My Life as a History Lesson and a Call to Action
Courtney Wells, PhD, MPH, MSWA Different World—Viewing Pediatric Rheumatology through a Global Lens
Laura Lewandowski, MD, MScMinding the Gap: Understanding and Addressing Representativeness and Disparities in Pediatric Rheumatology Research
Jennifer Woo, PhD, MPHGeneral Pediatric and Subspecialty Workforce Challenges and Potential Solutions
Speaker: Colleen Correll, MD, MPHPanel Discussion
Courtney Wells, PhD, MPH, MSW; Laura Lewandowski, MD, MSc; Jennifer Woo, PhD, MPH; Colleen Correll, MD, MPH
Clinical Management
Harnessing AI
Bella Mehta, MDFrom Promise to Practice: The Evolving Biosimilar Landscape in Pediatric Rheumatology
Ingrid Pan, PharmDWhat Do We Know About Vaccinations in Kids with Inflammatory Rheumatic Diseases?
Merav Heshin-Bekenstein, MD
Systemic Lupus Erythematosus
Pediatric Antiphospholipid Syndrome: A Few Bad aPLs
Jacqueline Madison, MDHitting the Target: Optimizing Outcomes in Childhood Lupus
Eve Smith, MD, PhD, BScMultitarget Therapy is Necessary for the Treatment of cSLE: A Great Debate
Hermine Brunner, MD, MSc, MBA, FAAP, FACR; and Aimee Hersh, MD, MS
Juvenile Idiopathic Arthritis
Not So Silent After All—Demystifying the Temporomandibular Joint
Marinka Twilt, MD, PhD, MScFrom Clues to Clarity: Axial Disease in Juvenile Spondyloarthritis
Pam Weiss, MDImaging as a Biomarker: Peripheral Joint Insights in JIA
Patricia Vega-Fernandez, MD, RhMSUS, MScPanel Discussion
Pam Weiss, MD; Marinka Twilt, MD, PhD, MSc; Patricia Vega-Fernandez, MD, RhMSUS, MSc
Clinical Update - Guidelines & Recommendations
Uveitis: Clinical Trials & PROs
Sheila Angeles Han, MD, MScMental Health Guidance Statements
Tamar Rubinstein, MD, MS
Juvenile Dermatomyositis and Scleroderma
Let’s Strengthen our Research in JDM: How to Perform and Collect Critical Measures in Clinical Practice
Kaveh Ardalan, MD, MS; Stacey Tarvin, MD, MS, FACR; Amy Rakestraw, PT, MPHGuidance for Stem Cell Therapy for Juvenile Systemic Sclerosis Patients
Kathryn Torok, MD
Vasculitis
Advancing Pediatric ANCA-Associated Vasculitis: Insights from Collaborative Research and Emerging Clinical Data
Jessica Bloom, MD, MSRenal Disease and Risk Stratification in Pediatric ANCA-associated Vasculitis (AAV)—Insights from the Pediatric Vasculitis Initiative
Kelly Brown, PhD
QI/Implementation
How to Integrate Data Elements into Clinical Care and Decision Making
Danielle Bullock, MD, MPHTransition Readiness
Melissa Argraves, MD, MEdPR-COIN: Improving JIA Outcomes
Julia Harris, MDMental Health Screening
Mileka Gilbert, MD, PhDPanel Discussion
Danielle Bullock, MD, MPH; Melissa Argraves, MD, MEd; Julia Harris, MD; Mileka Gilbert, MD, PhD
Systemic Juvenile Idiopathic Arthritis
Still's Disease—EULAR/PReS Recommendations
Fabrizio De Benedetti, MD, PhDIL-18 Inflammosopathy
Scott Canna, MDCAR-T Therapy: European Experience
Fabrizio De Benedetti, MD, PhDSituational Awareness for New Passengers in the CAR(-T)
Christen Ebens, MD, MPH
Target Audience
Rheumatologists, rheumatology interprofessionals, fellows in training, and residents.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the most up-to-date clinical information on the diagnosis and management of pediatric patients with rheumatic and immunologic disorders
Describe the most current information regarding the pathophysiology underlying pediatric rheumatic disorders
CE & MOC Information
In support of improving patient care, the American College of Rheumatology (ACR) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
See the ACR’s CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by March 30, 2029, at 11:59 PM ET.
All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied to the diplomate's number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to the Physician Portals. Please allow at least 48 hours for points to display in the portal.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.Available Credit
AMA PRA Category 1 Credit(s)™: 13.00
ABIM MOC: 13.00
ABP MOC: 13.00
AMA Designation Statement
The American College of Rheumatology designates this enduring material for a maximum of 13.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
MOC Recognition Statement: American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 13.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. PRSYM Highlights 2026 Financial Relationship Disclosures
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
The Pediatric Rheumatology Course 2023features key updates on a wide range of pediatric rheumatology diseases, including juvenile dermatomyositis, JIA, chronic nonbacterial osteomyelitis (CNO), Kawasaki disease, and mental health in children with rheumatic disease. The activity is well-suited for anyone who needs an update in the field of pediatric rheumatology.
The activity consists of recorded sessionsfrom several ACR 2023 live meetings: Pediatric Rheumatology Symposium,Education Exchange, and ACR Convergence. There are six lectures that range induration from 30 minutes to 2 hours and include a recorded Q&A session.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Target Audience
Primary care providers, rheumatologists, and rheumatology interprofessionals.
Learning Objectives
Upon completion of this activity, participants should be able to:
Review seminal work on calcinosis development
Analyze the strengths and limitations of different assessments of calcinosis, including imaging techniques
Review the evidence to support treatment decisions for calcinosis
List the multiple ways in which chronic nonbacterial osteomyelitis (CNO) may present in current pediatric rheumatology practice
Describe the role of whole body MRI in the detection and monitoring of CNO, relative to other imaging modalities
Describe the medications currently used for CNO and the available evidence supporting their use
Discuss the management of refractory non-systemic juvenile idiopathic arthritis (JIA) and uveitis
Discuss withdrawal of DMARDs for well-controlled, non-systemic JIA and uveitis, including timing, strategy, monitoring, and approach to flare
Review the 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease
Recognize mental health impact, current care practices, and gaps
Identify clinical practice change for optimized mental healthcare
Identify factors contributing to the relationship between rheumatologic disease and mental health in affected youth
Review recent advances in imaging of Takayasu arteritis (TAK) and how/when to use information from serial imaging to tailor treatments
Demonstrate which biologics have been studied in TAK and how this can be applied to the pediatric population
Review advances in vessel wall imaging in childhood primary angiitis of the central nervous system (cPACNS)
Discuss treatment protocols in cPACNS
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by August 29, 2027, at 11:59 PM ET.
All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied to the diplomate's number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to the Physician Portals. Please allow at least 48 hours for points to display in the portal.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
AMA Designation Statement
The AmericanCollege of Rheumatology designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MOC Recognition Statement: American Board of Pediatrics (ABP)
Successful completion of thisCME activity, which includes participation in the evaluation component, enables the learner to earn up to 6.75 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure thatContinuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
Authors
The following authors have no relevant financial relationship(s) with ineligible companies to disclose:
Hedrich, Christian, MD, PhD - Novartis, 2 (Terminated, August 31, 2021)
Ferguson, Polly, MD - No financial relationships with ineligible companies to disclose
Doria, Andrea, MD, PhD, MSc, MBA - Baxalta-Shire, 5 (Ongoing); Novo Nordisk, 5 (Ongoing); Terry Fox Foundation, 5(Ongoing)
Lood, Christian, PhD - No financial relationships with ineligible companies to disclose
Schiffenbauer, Adam, MD - AstraZeneca, 5 (Ongoing); Hope Pharmaceuticals, 5 (Ongoing)
Pilkington, Clarissa, MBBS, BSc,FRCPC, FRCP - No financial relationships with ineligible companies to disclose
Melissa Mannion, MD - No financial relationships with ineligible companies to disclose
Joost Swart, MD, PhD - No financial relationships with ineligible companies to disclose
Ashley M. Cooper, MD - No financial relationships with ineligible companies to disclose
Mark Gorelik, MD - No financial relationships with ineligible companies to disclose
Knight, Andrea, MD, MSCE - Pfizer, 6 (Ongoing)
Vora, Sheetal, MD, MS - No financial relationships with ineligible companies to disclose
Leever, Alana, PhD - No financial relationships with ineligible companies to disclose
Edison, Suzanne, MA, MFA - No financial relationships with ineligible companies to disclose
Susanne (Susa) Benseler, MD, PhD,FRCPC - No financial relationships with ineligible companies to disclose
Ozen, Seza, MD, MSc - No financial relationships with ineligible companies to disclose
Kaitlin Quinn, MD;MHS - No financial relationships with ineligible companies to disclose
Planning Team Members
The following editors and reviewers have no relevant financial relationship(s) with ineligible companies to disclose.
Adena Batterman, LCSW, MSW
Belina Yi, D.O.
Annelle Reed, MSN, CPNP
Kai Sun, MD, MS
Dawn Wahezi, MD, MS
Rebecca Manno, MD, MHS
Maura Daly Iversen, PT, DPT, SD, MPH,FNAP, FAPTA
Susan Farrow
Lawrence Cunningham
Carlos Ferreira, MA
Sharon Ross
Editors and Reviewers
The following editors and reviewers have relevant financial relationship(s) with ineligible companies to disclose.
Kaveh Ardalan, MD, MS – Cabaletta Bio, Inc. 1; Cure JM Foundation5
Susan Shenoi, MBBS, MS, RhMSUS – Pfizer2; Cabaletta Bio, Inc2; Novartis2; Amgen2
Lesley Ann Saketkoo, MD, MPH - Argenx1,5; Atyr1,5; Boehringer Ingelheim1,5; Horizon1,5; Janssen1,5; Kadmon1,5; Kinevant1,5; Kyverna1,5; Mallinckrodt1,5; Novartis1,5; UCB1,5
*All of the relevant financial relationships listed for these individuals have been mitigated.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
The Rheumatology Review Course 2023 features key updates covering a wide range of rheumatology diseases. This activity contains eight individual video lectures approximately 45 minutes in length, including a Q&A session, and is ideal for anyone needing an introduction to the latest research in rheumatology orsimply seeking an activity available at your convenience.
The Review Course is a popular session that takes place annually during ACR Convergence, the ACR’s annual meeting. Topics from the 2023 activity include:
Inflammatory eye disease diagnosis and treatment
Transition in juvenile idiopathic arthritis (JIA) care
Thrombotic microangiopathy
Relapsing polychondritis
Radiographic and non-radiographic ankylosing spondylitis
Systemic sclerosis screening for organ involvement
Reproductive counseling
Viral infections and rheumatic diseases
Target Audience
Rheumatologists, primary care providers physician assistants, fellows in training, advanced practice nurses, and rheumatology interprofessionals who care for patients with rheumatic diseases; professionals interested or engaged in rheumatology research.
Learning Objectives
Upon completion of this activity, participants should be able to:
Summarize up-to-date assessment and management strategies in inflammatory eye disease, polychondritis, and other rheumatic diseases
Identify current imaging modalities used to diagnose scleroderma, axial spondyloarthritis and thrombotic microangiopathy
Develop skills to facilitate open and accurate discussions about pregnancy prevention and planning
Define Juvenile Idiopathic Arthritis (JIA) including its etiology, symptoms, and common treatments
Demonstrate understanding of the unique challenges faced by young adults living with JIA
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by July 25, 2027, at 11:59 PM ET.
All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied to the diplomate's number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to the Physician Portals. Please allow at least 48 hours for points to display in the portal.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
Available Credit
CME: 6.00 AMA PRA Category 1 Credit(s)™
ABIM MOC: 6.00 Medical Knowledge Points
ABP MOC: 6.00 Lifelong Learning Points
AMA Designation Statement
The AmericanCollege of Rheumatology designates this Enduring Material for a maximum of 6.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: AmericanBoard of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MOC Recognition Statement: AmericanBoard of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 6.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure thatContinuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Rheumatology Review Course 2023 Financial Relationship Disclosures.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
ACR Convergence 2026 On Demand features recorded sessions from the premier international rheumatology meeting that took place in Chicago, Illinois. See cutting-edge insights across basic and clinical science with flexible, self-paced access to plenaries and symposia.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Target Audience
Advanced practice nurses, counselors, dietitians, division directors, epidemiologists, fellows in training, health service researchers, nurses, occupational therapists, office managers/staff, pharmacists, practice administrators, primary care providers, physical therapists, physician associates, program directors, psychologists, researchers, residents, rheumatologists, rheumatology interprofessionals, social workers / community health workers, and students.
Learning Objectives
Upon completion of this activity, participants should be able to:
Assess their knowledge and competence in various rheumatic diseases and conditions
Support their skills in evaluating and diagnosing patients with rheumatic diseases
Discuss and collaborate on challenging cases with peers
Analyze emerging trends and technologies in rheumatology
Employ evidence-based approaches for managing rheumatic conditions
Identify new approaches and strategies for patient management
Interpret recent clinical trial and research findings
Apply new information from basic and clinical science to improve the care of people with rheumatologic illness
CE & MOC
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by October 24, 2026, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for diplomates to the diplomate number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to physician portals. Please allow at least 48 hours for points to display in the portal.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Material for a maximum of 210.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 210.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MOC Recognition Statement: American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 210.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence 2025 On Demand Financial Relationship Disclosures
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.